Summary

This article discusses results from the late-breaking Study Comparing the Effect on Disease Activity When Reducing or Discontinuing Etanercept in Subjects with RA [DOSERA; NCT00858780]. The results showed that in patients with rheumatoid arthritis and stable low disease activity on methotrexate plus etanercept, continued treatment with etanercept at 25 or 50 mg/week provides a significantly higher likelihood of maintaining a stable disease state over 48 weeks than placebo.